Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | estrogen receptor 2 (ER beta) | References | |
Homo sapiens | estrogen receptor 1 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | estrogen receptor 2 (ER beta) | 495 aa | 418 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0159 | 0.9706 | 0.9706 |
Echinococcus multilocularis | 6 phosphofructo 2 kinase:fructose 2 | 0.0162 | 1 | 0.5 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0162 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0159 | 0.9706 | 0.9604 |
Mycobacterium ulcerans | hypothetical protein | 0.0096 | 0.2852 | 0.5 |
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.0096 | 0.2852 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0162 | 1 | 1 |
Schistosoma mansoni | 6-phosphofructokinase | 0.0162 | 1 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0096 | 0.2852 | 0.5 |
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.0096 | 0.2852 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0162 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.0159 | 0.9706 | 0.9706 |
Giardia lamblia | Hypothetical protein | 0.0096 | 0.2852 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.0159 | 0.9706 | 0.9706 |
Loa Loa (eye worm) | hypothetical protein | 0.0162 | 1 | 1 |
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.0159 | 0.9706 | 0.9706 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0162 | 1 | 1 |
Onchocerca volvulus | 0.0162 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Decrease (functional) | = -17.6 % | Percent decrease in serum cholesterol relative to OVX control at 0.1 mg/kg in rats | ChEMBL. | 9003514 |
Decrease (functional) | = 41.7 % | Percent decrease in serum cholesterol relative to OVX control at 1.0 mg/kg in rats | ChEMBL. | 9003514 |
Decrease (functional) | = 54 % | Percent decrease in serum cholesterol relative to OVX control at 10 mg/kg in rats | ChEMBL. | 9003514 |
ED50 (functional) | = 4 mg kg-1 | Dose required to reduce serum cholesterol by 50% relative to OVX controls was determined (in vivo) | ChEMBL. | 9003514 |
IC50 (functional) | = 5 nM | Antagonism of estrogen action in a mammary tumor cell line was assayed via inhibition of MCF-7 cell proliferation stimulated by 10 e-11 M 17-beta-estradiol (in vitro) | ChEMBL. | 9003514 |
IC50 (functional) | = 5 nM | Antagonism of estrogen action in a mammary tumor cell line was assayed via inhibition of MCF-7 cell proliferation stimulated by 10 e-11 M 17-beta-estradiol (in vitro) | ChEMBL. | 9003514 |
Increase (functional) | = 36.9 % | Minimum effective dose at which significant increase in uterine weight/body weight in rat was determined (in vivo); expressed as % increase relative to ovariectomized (OVX) controls | ChEMBL. | 9003514 |
MED (functional) | = 5 mg kg-1 | Minimum effective dose at which significant increase in uterine weight/body weight in rat was determined (in vivo) | ChEMBL. | 9003514 |
MED (functional) | > 10 mg kg-1 | Minimum effective dose at which significant increase in uterine eosinophil peroxidase (EPO) activity in rat was determined (in vivo) | ChEMBL. | 9003514 |
RBA (binding) | = 0.19 | In vitro relative binding affinity by competition with [3H]-17-beta-estradiol for estrogen receptor in MCF-7 cell lysate | ChEMBL. | 9003514 |
RBA (binding) | = 0.19 | In vitro relative binding affinity by competition with [3H]-17-beta-estradiol for estrogen receptor in MCF-7 cell lysate | ChEMBL. | 9003514 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.